REVIEW ARTICLE

Histology-based Treatment of Basal Cell Carcinoma

Klara MOSTERD, Aimee H.M.M. ARITS, Monique R.T. THISSEN and Nicole W.J. KELLENERS-SMEETS Department of Dermatology, University Hospital Maastricht, Maastricht, The Netherlands

Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising. In recent years, new treatment modalities have been developed and existing modalities refined. The aim of this article is to give a histology-based overview of the available evidence-based research. The literature was searched for randomized controlled trials from which the efficacy of investigated treatments was obtained. Where possible, treatment modalities were evaluated specifically. Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization. Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment. Key words: treatment; surgery; basal cell carcinoma; photodynamic therapy; radiotherapy; imiquimod.

(Accepted May 6, 2009.)

Acta Derm Venereol 2009; 89: 454-458.

Klara Mosterd, Department of Dermatology, Maastricht University Medical Centre, P. Debyelaan 25; PO box 5800, NL-6202 AZ Maastricht, The Netherlands. E-mail: k.mosterd@mumc.nl

Basal cell carcinoma (BCC) is the most common type of skin cancer and its incidence is still rising (1, 2). Between 1973 and 2000, the incidence of BCC in the Netherlands rose from 40 to 92 per 100,000 person-years in males and from 34 to 79 per 100,000 person-years in females and these numbers will continue to rise (2). Higher incidence rates are found in areas with more sun exposure, such as New Hampshire (USA) (310 per 100,000 men and 166 per 100,000 women in 1997) (3). Increasing (intermittent) ultraviolet radiation exposure is considered by some to be the main cause of the rise in incidence (4).

Surgical excision is a relatively simple treatment with high clearance rates, and therefore remains the mostused treatment modality worldwide. In recent years non-invasive therapies for selected low-risk BCC, such as photodynamic therapy (PDT), 5-fluorouracil (5-FU) and imiquimod 5% cream have increased in popularity, often showing excellent cosmetic outcomes (1).

A BCC can usually be diagnosed on the clinical aspect, but histological confirmation is necessary to determine the best treatment option (5). Although 26 histological subtypes have been described, clustering leads to a more practical classification (5–7).

The choice for a treatment modality should depend on the site, the size and whether the BCC shows indolent (superficial or nodular BCC) or aggressive growth (infiltrative BCC or basosquamous carcinoma) (5, 8). BCCs with mixed histology (almost 40%) should be treated according to their most aggressive histopathological subtype (5). Shave/punch biopsy specimens fail to diagnose one of both subtypes in approximately 20% of cases (5).

Only a few randomized controlled trials (RCTs) have investigated treatment modalities for BCCs. Because other studies are non-comparative and differ in inclusion criteria and treatment protocols, it is difficult to compare results (9). We shortly discuss available RCTs, and on the basis of available evidence we offer a histologybased guide for treatment of BCCs.

METHODS

All RCTs involving the treatment of histologically proven primary BCC (pBCC), published in the Cochrane review were included (1). Furthermore, the literature was searched for more recently published RCTs and RCTs concerning recurrent BCC (rBCC). Efficacy of each therapeutic approach was obtained from clearance rates. Cosmetic outcome was considered in cases of equal efficacy. Treatments were evaluated for specific tumour characteristics (primary or recurrent tumour, histological subtype and localization of the tumour). A practical classification of the histological subtype divided BCCs into three groups: superficial, nodular and aggressive BCC (BCCs with infiltrating and micro-nodular differentiation and basosquamous carcinoma) (8). Available RCTs were summarized (Tables I and II) and systematically discussed; first the results for surgical excision, followed by other invasive treatments and, finally, non-invasive treatment modalities.

RESULTS

Superficial basal cell carcinoma

Superficial BCC (sBCC) is often larger than other subtypes and occurs mainly on the trunk (10). Because of usually visible scarring after invasive treatment and a high risk of hypertrophic scar formation on the trunk, non-invasive treatment options might be a good alternative to surgery. Although the major benefit is a better aesthetic outcome, the absence of histological control is an important restriction of non-invasive treatments.

In two studies the effect of a treatment for sBCC was compared with that of excision (Table I). After 12 months, photodynamic therapy with methyl aminolevu-

	MAL-PDT100Head (mid-face excluded);90.790.7SE36Face (scalpel and neck)92.54RAL-PDT114Head, tunk; extremities93.3CT05ALA-PDT114Head, tunk; extremities93.3CT1717Head, tunk; extremities93.36CT1717NAL-PDT93.36CT1717Not mentioned8693.36CT22Head (note; extendities)93.311CT17Nume; extremities93.311Breadband halogen light134111Not mentioned8697.2Breadband halogen light13413497.297.297.2Verteporfini 120 J/cm ² 20110097.297.2Verteporfini 120 J/cm ² 24Not mentioned8697.2Verteporfini 120 J/cm ² 24Not mentioned8797.2Verteporfini 22 J/cm ² 24Not mentioned8797.2Imiquimod 2x/week25Limbs, trunk, head/neck97.217Imiquimod 2x/week25Limbs, trunk, head/neck97.2		Method evaluation CR	(months)	Cosmetic outcome	Conclusion
E. 50 Funk extremities 70 Chriselity with 48 27.5% packet Second mation 27.5% packet 27.5% packet <th27.5% packet<="" th=""> <th27.5% packet<="" th=""> 27.5</th27.5%></th27.5%>	DE 36 7 unus, extremites 100 SE 36 7 unus, extremites 92.5^{4} RT 41 Head, trunk; extremities 92.5^{4} CT 114 Head, trunk; extremities 93.3 CT 114 Head, trunk; extremities 93.3 CT 117 114 Head, trunk; extremities 93.3 CT 117 114 Head, trunk; extremities 93.3 CT 117 111 Not mentioned 86 Broadband halogen light 134 Head, neck; trunk; 86 Broadband halogen light 134 Head, neck; trunk; 86 Broadband halogen light 134 Not mentioned 86 Broadband halogen light 134 Not mentioned 86 Broadband balogen light 134 Not mentioned 86 Broadband balogen light 134 Not mentioned 86 Broadband balogen light 134 Not mentioned 87 Verteporfrin 180 J/cm ² 243 Not mentioned 87 Imiquimod $2x/week no243Limbs, trunk, head/neck100Imiquimod 2x/week26Limbs, trunk, head/neck100Imiquimod 2x/week100Limbs, trunk, head/neck123Imiquimod 2x/week100Limbs, trunk, head/neck100Imiquimod 2x/week100Limbs, trunk, head/neck100Imiquimod 2x/week33Limbs, trunk, head/neck100Imiquimod 2x/week33$	-	Clinically	12	94.1% excellent/good	
$ \begin{array}{cccc} RT & 11 & current contraction & 2.5 & histological confirmation & 0% good \\ CT & T & 11 & Head, trunk, currentities & 7 & 0.6 & 0.6% excellaring good \\ CT & T & 11 & Net metriconed & 5 & fistological examination & 0.6% excellaring good \\ Raser light & 111 & Net metriconed & 5 & fistological examination & 0.6% excellaring good \\ Raser light & 111 & Net metriconed & 5 & Glinically & 12 & 84% excellaring good \\ Raser light & 111 & Net metriconed & 5 & Glinically & 12 & 84% excellaring good \\ Wettepofiting 150 / term & 243 & Net metriconed & 37 & Glinically & 12 & 84% excellaring good \\ Wettepofiting 150 / term & 243 & Net metriconed & 37 & Glinically & 12 & 84% excellaring good \\ Wettepofiting 150 / term & 243 & Net metriconed & 37 & Glinically & 12 & 84% excellaring good \\ Wettepofiting 150 / term & 243 & Net metriconed & 37 & Glinically & 12 & 84% excellaring good \\ Wettepofiting 150 / term & 243 & Net metriconed & 37 & Glinically & 12 & 84% excellaring good \\ Wettepofiting 150 / term & 243 & Net mentioned & 37 & Glinically & 12 & Net mentioned \\ Single Illumination & 243 & Net metriconed & 37 & Glinically & 12 & Net mentioned \\ Single Illumination & 244 & Net metriconed & 37 & Glinically & 12 & Net mentioned \\ Single Illumination & 244 & Net metriconed & 37 & Glinically & 12 & Net mentioned \\ Single Illumination & 244 & Net metriconed & 37 & Glinically & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & For treatment excision & 12 & Net investigated \\ Imiguined & X/week & 0.0 & Post-treatment excision & 12 & Net investigated \\ Vetice cram & 0.0 & For t$	RT41excluded)92.5%MAL-PDT114Head; trunk; extremities78CTCT105Head (nose excluded);62ALA-PDT1717Head, trunk; extremities93.3CTCT22Head (nose excluded);63CTT11Not mentioned8693.3Verteporfrin 180 J/cm^2 120Head, neck; trunk;6397.2Verteporfrin 180 J/cm^2 23Not mentioned8097.2Verteporfrin 180 J/cm^2 23Not mentioned8097.2Verteporfrin 180 J/cm^2 23Not mentioned97.297.2Verteporfrin 180 J/cm^2 23Not mentioned8097.2Verteporfrin 180 J/cm^2 23Not mentioned8097.2Imiquimod 2x/week no24Limbs, trunk, head/neck1001Imiquimod 2x/week10Limbs, trunk, head/neck1001Imiquimod 2x/week25Limbs, trunk, head/neck7510Imiquimod 5x/week25Limbs, trunk, head/neck7510Imiquimod 5x/week33Limbs, trunk, head/neck7510Imiquimod 2x/week33Limbs, trunk, head/neck7510Imiquimod 5x/week33Limbs, trunk, head/neck7510Imiquimod 5x/week33Limbs, trunk, head/neck7510Imiquimod 2x/week33Limbs, trunk, head/neck7510Imiquimod 5x/week3	-	Clinically with	48	39.070 excentent/guou 87% good ^a	MAL-FUI Detter CO man SE SE higher CR than RT ^a
Cml CmlHad, truk, extentise3 -60 60° excellangoodALA-PDT14Had, truk, extentises3 -0° Head (nose excluded);2Histological examination12 93° excellangoodLar17Num, extremtises33 -0° hology33 -0° hology -39° excellangoodLar17Num, extremtises33 -0° hology -39° excellangoodLartipht120Head (nose excluded);23 -0° hology treated area -99° excellangoodVerteportin200 -0° exclorangood -0° -0° hology treated area -99° excellangoodSinge llumination24Not mentioned -9° -0° hology treated area -99° excellangoodSinge llumination24Not mentioned -9° -0° hology treated area -99° excellangoodSinge llumination24Not mentioned -9° -0° -0° -0° Inquinod 2x/veck24Limbs, trutk, head/neck 10° Post-treatment excision -0° -0° Inquinod 2x/veck23Limbs, trutk, head/neck 10° Post-treatment excision -0° -0° Inquinod 2x/veck23Limbs, trutk, head/neck 10° Post-treatment excision -0° -0° Inquinod 2x/veck23Limbs, trutk, head/neck 0° Post-treatment excision -0° -0° Inquinod 2x/veck23Limbs, tr	MAL-PDT114Head; trunk; extremities78CTCT117Nunk; extremities93.393.3CTCT17nunk; extremities93.393.3CTCT111Not mentioned8693.3CTCT111Not mentioned8693.3CTCT120Head, nock; trunk; extremities97.3Verteporfirin 100 J/cm ² 77extremities97.2Verteporfirin 180 J/cm ² 243Not mentioned89Verteporfirin 180 J/cm ² 201497.2Single illumination243Not mentioned97.2Single illumination243Not mentioned97.2Single illumination243Not mentioned97.2Imiquimod 2x/week no21(high risk areas excluded)37.1Imiquimod 3x/week23Limbs, trunk, head/neck75Imiquimod 3x/week26(high risk areas excluded)73.3Imiquimod 5x/week23Limbs, trunk, head/neck75Imiquimod 5x/week33Limbs, trunk, head/neck75Imiquimod 5x/week33Limbs, trunk, head/neck73.3Imiquimod 2x/day31(high risk areas excluded)73.3Imiquimod 2x/day33Limbs, trunk, head/neck75Imiquimod 2x/day33(high risk areas excluded)73.3Imiquimod 2x/day33Ininguimod 2x/day69.7Imiquimod 2x/day33Ininguimod 2x/day69.7 <td></td> <td>histological confirmation</td> <td></td> <td>69% good^a</td> <td>SE better CO than RT^a</td>		histological confirmation		69% good ^a	SE better CO than RT ^a
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	CT105Head (nose excluded);80ALA-PDT22Head (nose excluded);621TTrunk; extremities93.363CTTrunk; extremities93.363TVerteporfirin 60 J/cm^2 77extremities97.3Verteporfirin 180 J/cm^2 77extremities9763Verteporfirin 180 J/cm^2 80809763Verteporfirin 180 J/cm^2 243Not mentioned8997Verteporfirin 180 J/cm^2 80809763Single illumination243Not mentioned8997Fractionated illumination243Not mentioned8997Imiquimod 2x/week no243Not mentioned8973occlusion24(high risk areas excluded)78Imiquimod 2x/week25Iniquimod 2x/week8773Imiquimod 2x/week31(high risk areas excluded)73Miquimod 5x/week26Inibs, trunk, head/neck7517Imiquimod 5x/week26Inibs, trunk, head/neck7517Imiquimod 5x/week33Inips, trunk, head/neck7373Vehicle cream32Inips, trunk, head/neck7517Imiquimod 2x/week33Inips, trunk, head/neck7517Imiquimod 5x/week33Inips, trunk, head/neck7517Iniquimod 5x/week33Inips, trunk, head/neck7517Iniquim)		60% excellent/good	CT and MAL-PDT comparable CR
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	ALA-PDT22Head (nose excluded);621CTCT11Not mentioned8693CTTaser light13Head, neck; trunk;631Broadband halogen light13Head, neck; trunk;631Single illumination20243Not mentioned8797Verteporfinin 120 J/cm²7080979797Verteporfinin 180 J/cm²243Not mentioned9797Verteporfinin 180 J/cm²2010119797Single illumination2621101109797Eractionated Illumination262100139797Single illumination2621001110013Imiquimod 2x/week no21(high risk areas excluded)4397occlusion23110101011100Imiquimod 2x/week261001110011Imiquimod 2x/week33101001310Imiquimod 2x/week3310101310Imiquimod 5x/week331010131011Miquimod 5x/week33101010101Imiquimod 5x/week33101010101Imiquimod 5x/week33101010110Imiquimod 5x/week331010101Imiquimod 5				16% excellent/good	MAL-PDT better CO than CT
Cf 11 trunk: catternities 53.3 of hipsy 54% excellengood Bare fight 117 trunk: catternities 53.3 of hipsy 54% excellengood Vereportirin 10.01/err 21. trunk: catternities 53 excellengood Vereportirin 10.01/err 28 histological examination 59% excellengood Vereportirin 10.01/err 28 Not mentioned 55% excellengood Fractionated Iulumintion 243 Not mentioned 55% excellengood Imgiumod 2x/week occlusion 23 Linbs, trunk, had/neck 10 Post-treatment excision 6 Not mensigned Imgiumod 2x/week 28 Linbs, trunk, had/neck 7 Inicially Not investigated Iniquimod 2x/week 29 Post-treatment excision 6 Not investigated Iningiumod 2x/week	CT17trunk; extremities93.3Laser light111Not mentioned8693Broadband halogen light134Head; neck; trunk;8383Verteporfirin 120 J/cm ² 243Not mentioned8297Verteporfirin 120 J/cm ² 243Not mentioned8997Verteporfirin 120 J/cm ² 243Not mentioned8997Verteporfirin 120 J/cm ² 243Not mentioned8997Single illumination262Imiquimod 2×/week no21(high risk areas excluded)43miquimod 2×/week no21(high risk areas excluded)4397miquimod 2×/week no23Iniquimod 2×/week no2310011Iniquimod 2×/week no23Limbs, trunk, head/neck1001Imiquimod 2×/week13(high risk areas excluded)37.3Imiquimod 2×/week2910110Imiquimod 2×/week2910101Imiquimod 2×/week2910101Imiquimod 2×/week2910101Imiquimod 2×/week29101010Imiquimod 2×/week2910101Imiquimod 2×/week2910101Imiquimod 2×/week13(high risk areas excluded)7Imiquimod 2×/week33101010Imiquimod 2×/week331010Imiquimod 2×/week33<		Histological examination	12	93% excellent/good ^a	CT higher CR than MAL-PDT
Last light111Not mentioned86Clinically12R4% excellengoodBroadband hlogen light111Not mentioned86Clinically12R4% excellengoodVereporfirm 60 / cm ² 70120Head, neck; trunk;63Histological examination680% excellengoodVereporfirm 10.0 / cm ² 243Not mentioned97Clinically12R4% excellengoodSingle illumination243Not mentioned97Clinically12Not mentionedSingle illumination243Not mentioned93S5% excellengood5% excellengoodSingle illumination24Not mentioned93S5% excellengoodInquimod 3x/week noo23Linhs, trunk, had/neck10Post-treatment excision6Not investigatedInquimod 3x/week33Ultigh risk areas excluded)37.1Post-treatment excision12Not investigatedInquimod 3x/week33Ultigh risk areas excluded)37.1Post-treatment excision12Not investigatedInquimod 3x/week33Ultigh risk a	Laser light111Not mentioned860Broadband halogen light134Broadband halogen light13482Broadband halogen light134Head; neck; trunk;631Verteporfirin 180 J/cm ² 77extremities80Verteporfinin 180 J/cm ² 243Not mentioned82Verteporfinin 180 J/cm ² 243Not mentioned97Single illumination262Limbs, trunk, head/neck97Fractionated illumination262Limbs, trunk, head/neck97Imiquimod $2x/week$ no21(high risk areas excluded)43occlusion25Iniquimod $3x/week$ no2387miquimod $3x/week$ 29Limbs, trunk, head/neck1001Iniquimod $5x/week$ 26Inigh risk areas excluded)73Meticle cream179(high risk areas excluded)73Iniquimod $5x/week$ 29Limbs, trunk, head/neck75Iniquimod $5x/week$ 29Limbs, trunk, head/neck75Iniquimod $2x/day33(high risk areas excluded)73Vehicle cream33Limbs, trunk, head/neck90.7Iniquimod 2x/day33(high risk areas excluded)73Meticle cream179(high risk areas excluded)73Iniquimod 2x/day373.3(high risk areas excluded)73Vehicle cream33(high risk areas excluded)73Iniquimod 2x/day373.3(high risk areas excluded)6$	93.3	of biopsy		54% excellent/good ^a	ALA-PDT better CO than CT
	Broadband halogen light134Head; neck; trunk;82Verteporfirin $120 J/cm^2$ 7extremities97.2Verteporfirin $120 J/cm^2$ 70extremities97.2Verteporfirin $120 J/cm^2$ 70extremities97.2Verteporfirin $120 J/cm^2$ 24Not mentioned97Verteporfirin $120 J/cm^2$ 243Not mentioned97Verteporfirin $120 J/cm^2$ 243Not mentioned97Verteporfirin $120 J/cm^2$ 243Limbs, trunk, head/neck50Imiquimod $2x/week$ no21(high risk areas excluded)43occlusion25Limbs, trunk, head/neck100Imiquimod $3x/week$ 23Limbs, trunk, head/neck100Imiquimod $3x/week$ 26Inigh risk areas excluded)73Vehicle cream10Limbs, trunk, head/neck75Imiquimod $5x/week$ 28Limbs, trunk, head/neck75Imiquimod $5x/week$ 28Limbs, trunk, head/neck75Imiquimod $5x/week$ 29Limbs, trunk, head/neck75Imiquimod $2x/day$ 33(high risk areas excluded)73Vehicle cream360Limbs, trunk, head/neck90.7Imiquimod $2x/day$ 37.3Iniquimod $2x/day$ 73Vehicle cream33Limbs, trunk, head/neck90.7Imiquimod $2x/day$ 37.3Iniquimod $2x/day$ 73Vehicle cream30Limbs, trunk, head/neck90.7Imiquimod $2x/day$ 37.11010	86	Clinically	12	84% excellent/good	LL and BL comparable CR
Verteporfinin 001/cm ¹ 120 Head, neck, trunk; 63 Histological examination 68% excellent/good Verteporfinin 1001/cm ² 80 work of primation 233 Not mentioned 972 Clinically 12 Not mentioned Verteporfinin 1001/cm ² 80 nonethiopsy treated area 55% excellent/good Fractionated illumination 233 Not mentioned 972 Clinically 12 Not mentioned Fractionated illumination 233 Not mentioned 972 Clinically 12 Not mentioned Iniquimed 2x/week noc 21 (high risk areas excluded) 43 Post-treatment excision 6 Not investigated Iniquimed 2x/week noc 23 (high risk areas excluded) 87 Not investigated Iniquimed 2x/week 10 Limbs, trunk, head/neck 75 Post-treatment excision 12 Not investigated Iniquimed 2x/week 23 Limbs, trunk, head/neck 75 Post-treatment excision 12 Not investigated Iniquimod 5x/week 19 (high ri	Verteporfirin 60 J/cm²120Head; neck; trunk;631Verteporfirin 120 J/cm²77extremities80Verteporfirin 120 J/cm²77extremities80Verteporfirin 120 J/cm²73Not mentioned9763Fractionated illumination262Limbs, trunk, head/neck501Fractionated illumination243Not mentioned976Fractionated illumination262Limbs, trunk, head/neck501Imiquimod $3 \times$ /week no21(high risk areas excluded)43occlusion25Iniquimod $3 \times$ /week no230Imiquimod $3 \times$ /week no23(high risk areas excluded)73occlusion10Limbs, trunk, head/neck1001Imiquimod $3 \times$ /week26Limbs, trunk, head/neck751Imiquimod $3 \times$ /week28Limbs, trunk, head/neck751Imiquimod $3 \times$ /week33(high risk areas excluded)73Minquimod $3 \times$ /week33(high risk areas excluded)73Imiquimod $3 \times$ /week33(high risk areas excluded)73Imiquimod $3 \times$ /week33(high risk areas excluded)73Imiquimod $2 \times$ /day3179(high risk areas excluded)73Imiquimod $2 \times$ /day3179(high risk areas excluded)73Imiquimod $2 \times$ /day3(high risk areas excluded)73Imiquimod $2 \times$ /day3(high risk areas excluded)69 <td>82</td> <td></td> <td></td> <td>93% excellent/good</td> <td>LL and BL comparable CO</td>	82			93% excellent/good	LL and BL comparable CO
Wettportinn 20. punch biopsy treated area 65% excellengood Vertportinn 20.3 Not mentioned 7.2 Wort mentioned 55% excellengood Single illumination 22.3 Not mentioned 7.2 Not mentioned 55% excellengood Single illumination 22.3 Limbs, tunk, head/neck 50 Post-treatment excision 6 Not investigated Iniquimed 2x/week no 21 (high risk areas excluded) 43 Post-treatment excision 6 Not investigated Iniquimed 2x/week no 23 78 78 78 Not investigated Iniquimed 2x/week no 23 10 Limbs, tunk, head/neck 100 Post-treatment excision 6 Not investigated Iniquimed 2x/week 31 (high risk areas excluded) 73 1 10 Investigated Iniquimed 5x/week 31 (high risk areas excluded) 73 1 10 Investigated Iniquimed 5x/week 33 Limbs, tunk, head/neck 73 1 10 Investigated	Verteportiru 120 Jcm²77extremities80Verteportiru 180 Jcm²77809762Fractionated illumination262Limbs, trunk, head/neck501Fractionated illumination262Limbs, trunk, head/neck501Imiquimod $2 \times / week$ no21(high risk areas excluded)43occlusion25Limbs, trunk, head/neck1001Imiquimod $3 \times / week$ no23(high risk areas excluded)43occlusion25Imiquimod $3 \times / week$ no2378Imiquimod $3 \times / week$ no23(high risk areas excluded)80.8Imiquimod $3 \times / week$ 31(high risk areas excluded)73occlusion10Limbs, trunk, head/neck1001Imiquimod $3 \times / week$ 26Limbs, trunk, head/neck751.7Imiquimod $3 \times / week$ 26Limbs, trunk, head/neck751.7Imiquimod $3 \times / week$ 36Limbs, trunk, head/neck751.7Imiquimod $3 \times / week$ 36Limbs, trunk, head/neck7337.9Imiquimod $2 \times / day$ 3 $\lambda / week$ 361791001Imiquimod $2 \times / week$ 36Limbs, trunk, head/neck801.7Imiquimod $2 \times / week$ 3(high risk areas excluded)73.3Imiquimod $2 \times / week$ 3(high risk areas excluded)69.7Imiquimod $2 \times / day$ 3 $\lambda / week31013.3Vehicle crean31010$	63	Histological examination		80% excellent/good ^a	180 J/cm ² higher CR than both 120 and 60 J/cm ²
Single illumination24Not mentioned97Clinically12Not mentionedIniquimod $2\times$ /week occlusion24Uimbs, trunk, headneck30Post-treatment excision6Not investigatedIniquimod $2\times$ /week on23Limbs, trunk, headneck30Post-treatment excision6Not investigatedIniquimod $2\times$ /week no23Righ fisk areas excluded)3378Not investigatedIniquimod $2\times$ /week no23Righ fisk areas excluded)7378Not investigatedIniquimod $2\times$ /week10Limbs, trunk, head/neck100Post-treatment excision6Not investigatedIniquimod $2\times$ /week23Righ risk areas excluded)71Not investigated11Not investigatedIniquimod $2\times$ /week23Righ risk areas excluded)73Post-treatment excision6Not investigatedIniquimod $2\times$ /week23Righ risk areas excluded)73Post-treatment excision12Not investigatedIniquimod $2\times$ /week33Limbs, trunk, head/neck73Post-treatment excision12Not investigatedIniquimod $2\times$ /week33Limbs, trunk, head/neck73Post-treatment excision12Not investigatedIniquimod $2\times$ /week33Righ risk areas excluded)73Post-treatment excision12Not investigatedIniquimod $2\times$ /week34Righ risk areas excluded)73Post-treatment excision12Not investigatedIniquimod $2\times$ /day34 </td <td>Single illumination243Not mentioned97Fractionated illumination262Limbs, trunk, head/neck97Fractionated illumination262Limbs, trunk, head/neck97Imiquimod 2×/week no21(high risk areas excluded)43occlusion25Limbs, trunk, head/neck97Imiquimod 3×/week no2337887occlusion23niquimod 3×/week no23niquimod 3×/week no2310Limbs, trunk, head/neck100Imiquimod 3×/week31(high risk areas excluded)87.1Imiquimod 3×/week2617980.8Imiquimod 3×/week2617951.7Imiquimod 3×/week2617973Imiquimod 5×/week36Limbs, trunk, head/neck75Imiquimod 7×/week33(high risk areas excluded)73Vehicle cream82Limbs, trunk, head/neck80Imiquimod 2×/day33(high risk areas excluded)73Vehicle cream33Limbs, trunk, head/neck90Imiquimod 1×/day33(high risk areas excluded)69Imiquimod 1×/day33Limbs, trunk, head/neck90Imiquimod 1×/day33(high risk areas excluded)69Imiquimod 1×/day33Limbs, trunk, head/neck90Imiquimod 1×/day33(high risk areas excluded)87.9Imiquimod 1×/day33Limbs, trunk, head/neck90Imiquimod 1×/day33Li</td> <td>80 97.7</td> <td>punch biopsy treated area</td> <td></td> <td>65% excellent/good 55% excellent/good</td> <td>60 J/cm² higher CO than both 120 and 180 J/cm²</td>	Single illumination243Not mentioned97Fractionated illumination262Limbs, trunk, head/neck97Fractionated illumination262Limbs, trunk, head/neck97Imiquimod 2×/week no21(high risk areas excluded)43occlusion25Limbs, trunk, head/neck97Imiquimod 3×/week no2337887occlusion23niquimod 3×/week no23niquimod 3×/week no2310Limbs, trunk, head/neck100Imiquimod 3×/week31(high risk areas excluded)87.1Imiquimod 3×/week2617980.8Imiquimod 3×/week2617951.7Imiquimod 3×/week2617973Imiquimod 5×/week36Limbs, trunk, head/neck75Imiquimod 7×/week33(high risk areas excluded)73Vehicle cream82Limbs, trunk, head/neck80Imiquimod 2×/day33(high risk areas excluded)73Vehicle cream33Limbs, trunk, head/neck90Imiquimod 1×/day33(high risk areas excluded)69Imiquimod 1×/day33Limbs, trunk, head/neck90Imiquimod 1×/day33(high risk areas excluded)69Imiquimod 1×/day33Limbs, trunk, head/neck90Imiquimod 1×/day33(high risk areas excluded)87.9Imiquimod 1×/day33Limbs, trunk, head/neck90Imiquimod 1×/day33Li	80 97.7	punch biopsy treated area		65% excellent/good 55% excellent/good	60 J/cm ² higher CO than both 120 and 180 J/cm ²
Fractionated filturination26Not investigatedIniquimod 2x/week occlusion24Limbs, trunk, headneck50Post-treatment excision6Not investigatedIniquimod 2x/week no21(high risk areas excluded)43SSNot investigatedIniquimod 2x/week no2310Limbs, trunk, headneck100Post-treatment excision6Not investigatedIniquimod 2x/week no2310Limbs, trunk, headneck100Post-treatment excision6Not investigatedIniquimod 2x/week268710Limbs, trunk, headneck100Post-treatment excision6Not investigatedIniquimod 2x/week25878780Post-treatment excision12Not investigatedIniquimod 2x/week10Limbs, trunk, head/neck100Post-treatment excision12Not investigatedIniquimod 2x/week13(high risk areas excluded)73Post-treatment excision12Not investigatedIniquimod 2x/week33Limbs, trunk, head/neck77Post-treatment excision12Not investigated<	Fractionated illumination262Imiquimod 2x/week no21Imiquimod 2x/week no21Imiquimod 2x/week no21occlusion25Imiquimod 3x/week no25Imiquimod 3x/week no23occlusion25Imiquimod 3x/week no23niquimod 3x/week no23niquimod 3x/week no23niquimod 3x/week no23niquimod 3x/week no23niquimod 3x/week no23niquimod 3x/week no26Imiquimod 3x/week26Imiquimod 3x/week26Imiquimod 3x/week26Imiquimod 3x/week26Imiquimod 3x/week26Imiquimod 5x/week26Imiquimod 5x/week26Imiquimod 5x/week33Vehicle cream80Imiquimod 1x/day33Imiquimod 1x/day10Imiquimod 1x/day33Imiquimod 1x/day33Imiquimod 1x/day33Imiquimod 1x/day33Imiquimod 1x/day33Imiquim	21/0	Clinically	12	Not mentioned	Fractionated illumination higher CR than single
Imiquimod 2x/week occlusion21Limbs, trunk, head/neck50Post-treatment excision6Not investigatedIniquimod 2x/week onclusion2378787878Iniquimod 2x/week onclusion23787878Iniquimod 2x/week onclusion23787878Iniquimod 2x/week onclusion23787878Iniquimod 2x/week onclusion23787878Iniquimod 2x/week31(high risk areas excluded)87.178Iniquimod 2x/week2680.17374Iniquimod 5x/week2680.380.880.8Iniquimod 5x/week2680.17374Iniquimod 5x/week2680.880.875Iniquimod 5x/week19(high risk areas excluded)7374Iniquimod 5x/week1875Post-treatment excision12Not investigatedIniquimod 7x/week361.imbs, trunk, head/neck75Post-treatment excision12Not investigatedIniquimod 7x/week331.imbs, trunk, head/neck80Post-treatment excision12Not investigatedIniquimod 2x/day331.imbs, trunk, head/neck80Post-treatment excision12Not investigatedIniquimod 2x/day331.imbs, trunk, head/neck90Post-treatment excision12Not investigatedIniquimod 2x/day331.imbs, trunk, head/neck90Post-treatment excision12<	Imiquimod 2×/week occlusion24Limbs, trunk, head/neck50Imiquimod 2×/week no21(high risk areas excluded)43occlusion25(high risk areas excluded)43Imiquimod 3×/week no2378niquimod 3×/week no2378niquimod 3×/week no2378niquimod 1×/day10Limbs, trunk, head/neck100Imiquimod 5×/week2687.1Imiquimod 5×/week2951.7Vehicle cream32Limbs, trunk, head/neck75Imiquimod 5×/week179(high risk areas excluded)73Vehicle cream36179(high risk areas excluded)73Vehicle cream36179(high risk areas excluded)73Vehicle cream33Limbs, trunk, head/neck80Miquimod 2×/day33(high risk areas excluded)87.9Imiquimod 1×/day33(high risk areas excluded)87.9Imiquimod 1×/day34Limbs, trunk, head/neck90Imiquimod 1×/day32Limbs, trunk, head/neck90Imiquimod 1×/day32Limbs, trunk, head/neck90Imiquimod 1×/day33Limbs, trunk, head/neck90 <tr<< td=""><td>89</td><td>Cumouny</td><td>1</td><td></td><td>illumination</td></tr<<>	89	Cumouny	1		illumination
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Imiquimod 2×/week no21(high risk areas excluded)43occlusion2578Imiquimod 3×/week no2378niquimod 3×/week no2378niquimod 3×/week no2378niquimod 1×/day10Limbs, trunk, head/neck100Imiquimod 5×/week2687.1Imiquimod 5×/week2687.1Imiquimod 5×/week2987.1Imiquimod 5×/week2917Vehicle cream32179Imiquimod 5×/week179(high risk areas excluded)Timiquimod 5×/week84Limbs, trunk, head/neckNehicle cream3673Vehicle cream30Imiquimod 2×/dayImiquimod 1×/day33(high risk areas excluded)Miquimod 1×/day33(high risk areas excluded)Miquimod 1×/day33(high risk areas excluded)Imiquimod 1×/day33(high risk areas excluded)Imiquimod 1×/day33(high risk areas excluded)Miquimod 1×/day31Limbs, trunk, head/neckMiquimod 1×/day32Limbs, trunk, head/neckImiquimod 1×/day32Limbs, trunk, head/neckImiquimod 1×/day32Limbs, trunk, head/neckMiquimod 1×/day32Limbs, trunk, head/neckMiquimod 1×/day32Limbs, trunk, head/neckMiquimod 1×/day32Limbs, trunk, head/neckMiquimod 1×/day33Limbs, trunk, head/neckMiquimod 1×/day10Limbs, t		Post-treatment excision	9	Not investigated	Best results after imiguimod 3x/week without occlusion
niquimod 3x/week no 25 78 imquimod 3x/week no 25 78 imquimod 3x/week no 23 78 occlusion 21 000 Imquimod 2x/day 10 Limbs, trunk, head/neck 100 Imquimod 2x/day 10 Limbs, trunk, head/neck 100 Imquimod 2x/week 29 87.1 80.8 Imiquimod 5x/week 29 81.1 80.8 Imiquimod 5x/week 29 81.1 80.8 Imiquimod 5x/week 29 81.1 80.8 Imiquimod 5x/week 179 600 90.1 Imiquimod 5x/week 179 600 75 Post-treatment excision Imiquimod 5x/week 179 600 Post-treatment excision 12 Not investigated Imiquimod 7x/week 29 100 Post-treatment excision 12 Not investigated Vehicle cream 30 100 10 Post-treatment excision 12 Not investigated Vehicle cream 33 100 100 Post-treatment excision 12 Not investigated	occlusion2578Imiquimod 3x/week occlusion2387Imiquimod 3x/week no2387occlusion2387Imiquimod 2x/day10Limbs, trunk, head/neck100Imiquimod 5x/week2610087.1Imiquimod 5x/week2680.881.7Imiquimod 5x/week2610087.1Imiquimod 5x/week2618511.7Vehicle cream3211.8518.8Imiquimod 5x/week17510073Vehicle cream360179(high risk areas excluded)73Vehicle cream360179(high risk areas excluded)6Imiquimod 7x/week84Limbs, trunk, head/neck80Vehicle cream360Limbs, trunk, head/neck80Imiquimod 2x/day33(high risk areas excluded)6Imiquimod 1x/day33Limbs, trunk, head/neck90FFU in PC10Limbs, trunk, head/neck905.FU in petrolatum7(facial BCC)571.0 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90*0.5 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90*	(p				Occlusion has no effect on efficacy
Imiquimod 3x/week no 23 78 Iniquimod 3x/week no 23 87 Iniquimod 3x/week no 23 87 Iniquimod 2x/day 10 Linbs, trunk, head/neck 100 Post-treatment excision 6 Not investigated Iniquimod 2x/week 26 Uigh risk areas excluded) 87.1 1 Not investigated Iniquimod 5x/week 185 Linbs, trunk, head/neck 75 Post-treatment excision 12 Not investigated Iniquimod 5x/week 185 Linbs, trunk, head/neck 75 Post-treatment excision 12 Not investigated Iniquimod 7x/week 179 (ligh risk areas excluded) 7 Post-treatment excision 12 Not investigated Vehicle cream 82 Linbs, trunk, head/neck 80 Post-treatment excision 12 Not investigated Vehicle cream 82 Iniquimod 2x/day 3 Ininbs, trunk, head/neck 9 Post-treatment excision 12 Not investigated Vehicle cream 82 (ligh risk areas excluded) 6 <	Imiquimod $3\times$ week occlusion2578Imiquimod $3\times$ week no2387occlusion2387Imiquimod $3\times$ week no2310Imiquimod $2\times$ day10Limbs, trunk, head/neck80.8Imiquimod $3\times$ week2681.7Imiquimod $5\times$ week2680.8Imiquimod $5\times$ week2981.7Vehicle cream32179Imiquimod $5\times$ week179Imiquimod $5\times$ week179Imiquimod $5\times$ week179Imiquimod $7\times$ week179Imiquimod $7\times$ week179Vehicle cream360Vehicle cream30Imiquimod $2\times$ day33Imiquimod $2\times$ day33Imiquimod $2\times$ day33Imiquimod $2\times$ day33Imiquimod $1\times$ day33Imiquimod $1\times$ day35Imiquimod $1\times$ day10Imiquimod $1\times$ day35Imiquimod $1\times$ day35Imiquimod $1\times$ day10Imiquimod $1\times$ day35Imiquimod $1\times$ day35					
Imiquimod 38787occlusioncoclusioncoclusionocclusionIniquimod 2×(day10Limbs, trunk, head/neck100Post-treatment excision6Not investigatedIniquimod 5×(week2680.880.880.880.880.880.880.8Imiquimod 5×(week2680.880.880.880.880.880.8Iniquimod 5×(week2980.880.880.880.880.8Iniquimod 5×(week1880.880.880.880.8Iniquimod 5×(week1880.880.880.880.8Iniquimod 5×(week1880.880.880.880.8Iniquimod 5×(week1875Post-treatment excision12Not investigatedIniquimod 7×(week84Limbs, trunk, head/neck8080.7Post-treatment excision12Not investigatedIniquimod 7×(week31Limbs, trunk, head/neck90Post-treatment excision12Not investigatedIniquimod 1×(day, 3×(week31Limbs, trunk, head/neck90Post-treatment excision12<	Imiquimod $3\times$ /week no2387occlusionImiquimod $2\times$ /day10Limbs, trunk, head/neck100Imiquimod $2\times$ /day10Limbs, trunk, head/neck87.1Imiquimod $5\times$ /week2687.180.8Imiquimod $5\times$ /week2610087.1Imiquimod $5\times$ /week2610087.1Imiquimod $5\times$ /week261780.8Imiquimod $5\times$ /week291781.8Imiquimod $5\times$ /week1751781.8Imiquimod $5\times$ /week1751717Vehicle cream360732Imiquimod $7\times$ /week84Limbs, trunk, head/neck80Vehicle cream30Inigh risk areas excluded)6Imiquimod $2\times$ /day33(high risk areas excluded)87.9Imiquimod $2\times$ /day33(high risk areas excluded)87.9Imiquimod $1\times$ /day3510010073.3Imiquimod $1\times$ /day3510010073.3Imiquimod $1\times$ /day3510010057Iniquimod $1\times$ /day3510010055.70Iniquimod $1\times$ /day7(facial BCC)57Iniquimod 5 -FU in PC101015.7057I.0 ml 5 -FU $1\times$ /week, 6 weeks20Limbs, trunk, head/neck90*Imiquimod 1 7(facial BCC)57I.0 ml 5 -FU $1\times$ /week is week20Limbs, trunk, head/neck90*	78				
occlusionocclusionImiquimod $2x/day$ 10Limbs, trunk, head/neck100Post-treatment excision6Not investigatedImiquimod $3x/week$ 2651.780.880.880.8Imiquimod $5x/week$ 2951.7Not investigated292951.7Not investigatedVehicle cream32Limbs, trunk, head/neck75Post-treatment excision12Not investigatedImiquimod $5x/week$ 185Limbs, trunk, head/neck75Post-treatment excision12Not investigatedVehicle cream360(high risk areas excluded)73Post-treatment excision12Not investigatedImiquimod $7x/week$ 84Limbs, trunk, head/neck100Post-treatment excision12Not investigatedVehicle cream36Limbs, trunk, head/neck6Post-treatment excision12Not investigatedImiquimod $7x/week$ 31Limbs, trunk, head/neck100Post-treatment excision12Not investigatedVehicle cream30Limbs, trunk, head/neck90Post-treatment excision12Not investigatedVehicle cream33Limbs, trunk, head/neck90Post-treatment excision12Not investigatedVehicle cream33Limbs, trunk, head/neck90Post-treatment excision12Not investigatedVehicle cream33Limbs, trunk, head/neck90Post-treatment excision12Not investigatedVehicle cream <td>occlusionocclusionImiquimod $2x/day$10Limbs, trunk, head/neck100Imiquimod $1x/day$31(high risk areas excluded)87.1Imiquimod $5x/week$2680.8Imiquimod $3x/week$2981.7Vehicle cream32Limbs, trunk, head/neck51.7Imiquimod $5x/week$291787.1Vehicle cream32Limbs, trunk, head/neck75Imiquimod $5x/week$179(high risk areas excluded)73Vehicle cream360732Imiquimod $7x/week$84Limbs, trunk, head/neck80Vehicle cream36(high risk areas excluded)6Imiquimod $2x/day$33(high risk areas excluded)87.9Imiquimod $1x/day$33(high risk areas excluded)87.9Imiquimod $1x/day$35.7Limbs, trunk, head/neck90Minquimod $1x/day$37.910100Imiquimod $1x/day$37.91057Imiquimod $1x/day$37.0Limbs, trunk, head/neck905.FU in PC10Limbs, trunk, head/neck905.FU in petrolatum7(facial BCC)571.0 ml 5-FU $1x/week$, 6 weeks20Limbs, trunk, head/neck90*</td> <td>87</td> <td></td> <td></td> <td></td> <td></td>	occlusionocclusionImiquimod $2x/day$ 10Limbs, trunk, head/neck100Imiquimod $1x/day$ 31(high risk areas excluded)87.1Imiquimod $5x/week$ 2680.8Imiquimod $3x/week$ 2981.7Vehicle cream32Limbs, trunk, head/neck51.7Imiquimod $5x/week$ 291787.1Vehicle cream32Limbs, trunk, head/neck75Imiquimod $5x/week$ 179(high risk areas excluded)73Vehicle cream360732Imiquimod $7x/week$ 84Limbs, trunk, head/neck80Vehicle cream36(high risk areas excluded)6Imiquimod $2x/day$ 33(high risk areas excluded)87.9Imiquimod $1x/day$ 33(high risk areas excluded)87.9Imiquimod $1x/day$ 35.7Limbs, trunk, head/neck90Minquimod $1x/day$ 37.910100Imiquimod $1x/day$ 37.91057Imiquimod $1x/day$ 37.0Limbs, trunk, head/neck905.FU in PC10Limbs, trunk, head/neck905.FU in petrolatum7(facial BCC)571.0 ml 5-FU $1x/week$, 6 weeks20Limbs, trunk, head/neck90*	87				
Imiquimod $2x/day$ 10Limbs, trunk, head/neck100Post-treatment excision6Not investigatedImiquimod $1x/day$ 31(high risk areas excluded)87.187.1Not investigatedImiquimod $5x/week$ 2951.78.881.7Vehicle cream32Limbs, trunk, head/neck75Post-treatment excision12Not investigatedImiquimod $7x/week$ 179(high risk areas excluded)73Post-treatment excision12Not investigatedImiquimod $7x/week$ 360Post-treatment excision12Not investigatedImiquimod $7x/week$ 34Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream36073Post-treatment excision12Not investigatedImiquimod $7x/week$ 3Limbs, trunk, head/neck100Post-treatment excision12Not investigatedVehicle cream33(high risk areas excluded)87.9Post-treatment excision12Not investigatedImiquimod $2x/day$ 3Limbs, trunk, head/neck100Post-treatment excision12Not investigatedIniquimod $2x/day$ 3Limbs, trunk, head/neck90Post-treatment excision12Not investigatedTo inform7(facial BCC)73Post-treatment excision12Not investigatedIniquimod $2x/day$ 3Limbs, trunk, head/neck90Post-treatment excision12Not investigatedIniquimod 1	Imiquimod $2\times/day$ 10Limbs, trunk, head/neck100Imiquimod $1\times/day$ 31(high risk areas excluded)87.1Imiquimod $5\times/week$ 2680.8Imiquimod $5\times/week$ 2681.7Vehicle cream32Limbs, trunk, head/neck51.7Imiquimod $5\times/week$ 179(high risk areas excluded)87.1Imiquimod $5\times/week$ 179(high risk areas excluded)73Imiquimod $5\times/week$ 179(high risk areas excluded)73Vehicle cream360179(high risk areas excluded)6Imiquimod $7\times/week$ 84Limbs, trunk, head/neck80Vehicle cream33(high risk areas excluded)6Imiquimod $2\times/day$ 33(high risk areas excluded)69.7Imiquimod $1\times/day$ 33(high risk areas excluded)87.9Imiquimod $1\times/day$ 33(high risk areas excluded)87.9Imiquimod $1\times/day$ 3.5-FU in PC10100S-FU in petrolatum7(facial BCC)570.5 ml 5 -FU 1 x/week, 6 weeks20Limbs, trunk, head/neck90°					
Imagemend X/day 31(high risk areas excluded)87.1Imiquimod $X/week$ 260.80.8Imiquimod $X/week$ 261.70.8Imiquimod $X/week$ 185Limbs, trunk, head/neck75Post-treatment excision12Nehicle cream32Limbs, trunk, head/neck75Post-treatment excision12Not investigatedImiquimod $7x/week$ 179(high risk areas excluded)73Post-treatment excision12Not investigatedImiquimod $7x/week$ 84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream36010Post-treatment excision12Not investigatedVehicle cream33(high risk areas excluded)87.9Post-treatment excision12Not investigatedVehicle cream33(high risk areas excluded)87.9Post-treatment excision12Not investigatedVehicle cream33(high risk areas excluded)87.9Post-treatment excision12Not investigatedImiquimod $2x/day, 3x/week$ 30Ininbs, trunk, head/neck90Post-treatment excision12Not investigatedImiquimod $2x/day, 3x/week33(high risk areas excluded)87.9Post-treatment excision12Not investigatedImiquimod 2x/day, 3x/week33(high risk areas excluded)87.9Post-treatment excision12Not investigatedImiquimod 2x/day, 3x/week33(high risk areas excluded)<$	Imiquimod $1x/day$ 31(high risk areas excluded)87.1Imiquimod $5x/week$ 26100.8Imiquimod $5x/week$ 2651.7Vehicle cream321185Imiquimod $5x/week$ 1851185Imiquimod $5x/week$ 1851185Imiquimod $5x/week$ 179(high risk areas excluded)Topicite cream36073Vehicle cream82(high risk areas excluded)Imiquimod $7x/week$ 84Limbs, trunk, head/neckWeinice cream32(high risk areas excluded)Imiquimod $1x/day$ 33(high risk areas excluded)Imiquimod $1x/day$ 32100Imiquimod $1x/day$ 33(high risk areas excluded)Imiquimod $1x/day$ 32100Imiquimod $1x/day$ 33100Imiquimod $1x/day$ 33100Imiduimod $1x/day$ 33 <t< td=""><td>-</td><td>Post-treatment excision</td><td>9</td><td>Not investigated</td><td>Dosage 1×/day or 5×/week highest efficacy with</td></t<>	-	Post-treatment excision	9	Not investigated	Dosage 1×/day or 5×/week highest efficacy with
Imiquimod 5x/week2680.8Imiquimod 5x/week2951.7Vehicle cream3251.7Neininod 5x/week18.818.8Imiquimod 5x/week179(high risk areas excluded)75Post-treatment excision12Imiquimod 5x/week179(high risk areas excluded)73Vehicle cream36074Vehicle cream36075Not investigated76Not investigated76Not investigated77Not investigated73Imiquimod 2x/day74Not investigated75Not investigated76Not investigated77SFU in PC76100771007710076100771007610077100771007610077100771007610077100761007710076100771007610077100761007710076100771007610077100761007710076100771007610077100761007710076	Imiquimod $5\times$ /week2680.8Imiquimod $3\times$ /week2951.7Vehicle cream32185Imiquimod $5\times$ /week185Limbs, trunk, head/neckTimiquimod $7\times$ /week179(high risk areas excluded)Timiquimod $7\times$ /week84Limbs, trunk, head/neckNehicle cream3602Imiquimod $7\times$ /week84Limbs, trunk, head/neckNehicle cream82(high risk areas excluded)Nehicle cream33Limbs, trunk, head/neckNehicle cream33(high risk areas excluded)Imiquimod $2\times$ /day33Limbs, trunk, head/neckImiquimod $2\times$ /day33(high risk areas excluded)Imiquimod $2\times$ /day33(high risk areas excluded)Imiquimod $1\times$ /day, $3\times$ /week30Limbs, trunk, head/neck 0.5 FU in PC10Limbs, trunk, head/neck 0.5 ml 5 -FU in petrolatum7(facial BCC) 57 1.0 ml 5 -FU 1 x/week, 6 weeks20 0.5 ml 5 -FU 1 x/week, 6 weeks21(high risk areas excluded) 0.5 ml 5 -FU 1 x/week, 6 weeks21(high risk areas excluded)					acceptable safety profiles
Imquimod $3x$ /week2951.7Vehicle cream32Linbs, trunk, head/neck75Post-treatment excision12Not investigatedImquimod $7x$ /week179(high risk areas excluded)73Post-treatment excision12Not investigatedWehicle cream3602Post-treatment excision12Not investigatedWehicle cream3602Post-treatment excision12Not investigatedMiquimod $7x$ /week84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedWehicle cream3(high risk areas excluded)6Post-treatment excision12Not investigatedImiquimod $2x/day$ 3(high risk areas excluded)87.9Post-treatment excision12Not investigatedImiquimod $2x/day$ 3(high risk areas excluded)90°Post-treatment excision12Not investigatedImiquimod $2x/day$ 3(high risk areas excluded)97.990°91.00%90°Induition $2x/day$ 3(high risk areas excluded)91.092.490°FUU in PErCU $2x/week$, 4 weeks <td< td=""><td>Imiquimod 3x/week2951.7Vehicle cream32185Limbs, trunk, head/neck75Imiquimod 7x/week185Limbs, trunk, head/neck75Imiquimod 7x/week179(high risk areas excluded)73Vehicle cream3603602Imiquimod 7x/week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Imiquimod 2x/day33(high risk areas excluded)6Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day32Inibs, trunk, head/neck906.FU in PC10Limbs, trunk, head/neck906.5 m 15-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90*70.5 m 15-FU 1x/week, 6 weeks21(high risk areas excluded)95*</td><td>80.8</td><td></td><td></td><td></td><td></td></td<>	Imiquimod 3x/week2951.7Vehicle cream32185Limbs, trunk, head/neck75Imiquimod 7x/week185Limbs, trunk, head/neck75Imiquimod 7x/week179(high risk areas excluded)73Vehicle cream3603602Imiquimod 7x/week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Imiquimod 2x/day33(high risk areas excluded)6Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day33(high risk areas excluded)69.7Imiquimod 1x/day32Inibs, trunk, head/neck906.FU in PC10Limbs, trunk, head/neck906.5 m 15-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90*70.5 m 15-FU 1x/week, 6 weeks21(high risk areas excluded)95*	80.8				
Vehicle cream32 Imiguimod 5x/week18 18Is.8 InivestigatedImiguimod 5x/week18 5Limbs, trunk, head/neck75 5Post-treatment excision12Not investigatedImiguimod 7x/week179(high risk areas excluded)732Not investigatedImiguimod 7x/week84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream82(high risk areas excluded)67Not investigatedVehicle cream33Limbs, trunk, head/neck80Post-treatment excision12Not investigatedImiguimod 2x/day33Limbs, trunk, head/neck100Post-treatment excision12Not investigatedImiquimod 2x/day33(high risk areas excluded)73.369.7Not investigatedImiquimod 2x/day33(high risk areas excluded)73.357Not investigatedImiquimod 2x/day10Limbs, trunk, head/neck90Post-treatment excision12Not investigated5-FU in PC10Limbs, trunk, head/neck90Post-treatment excision12Not investigated0.5 ml 5-FU 1x/week, 6 weeks2Limbs, trunk, head/neck90*Post-treatment excision12Not investigated0.5 ml 5-FU 1x/week, 4 weeks100*0*Post-treatment excision12Not investigated0.5 ml 5-FU 2x/week, 4 weeks10*0*Post-treatment excision12Not investigated0.5	Vehicle cream32Imiquimod 5x/week185Limbs, trunk, head/neck75Imiquimod 7x/week179(high risk areas excluded)73Vehicle cream36084Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)2Imiquimod 7x/week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Imiquimod 1x/day33(high risk areas excluded)6Imiquimod 1x/day33(high risk areas excluded)73.3Imiquimod 1x/day, 3x/week30Limbs, trunk, head/neck905-FU in PC10Limbs, trunk, head/neck900.5 ml 5-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90*	51.7				
Imiquimod 5x/week185Limbs, trunk, head/neck75Post-treatment excision12Not investigatedImiquimod 7x/week179(high risk areas excluded)732Not investigatedVehicle cream360179(high risk areas excluded)73Not investigatedImiquimod 7x/week84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream82(high risk areas excluded)6Post-treatment excision12Not investigatedImiquimod 2x/day33Limbs, trunk, head/neck100Post-treatment excision12Not investigatedImiquimod 2x/day33(high risk areas excluded)87.9999Imiquimod 2x/day33Limbs, trunk, head/neck90Post-treatment excision12Not investigatedImiquimod 2x/day33Limbs, trunk, head/neck90Post-treatment excision12Not investigatedImiquimod 2x/day33Limbs, trunk, head/neck90Post-treatment excision12Not investigatedImiquimod 2x/day3x/week3Limbs, trunk, head/neck90Post-treatment excision12Not investigatedImiquimod 2x/day3Interolutum5790Post-treatment excision12Not investigatedImiquimod 2x/day3Interolutum5790Post-treatment excision12Not investigatedImiquimod 1x/day10105790Post-trea	Imiquimod 5x/week185Limbs, trunk, head/neck75Imiquimod 7x/week179(high risk areas excluded)73Vehicle cream3603602Imiquimod 7x/week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Imiquimod 7x/week33(high risk areas excluded)6Imiquimod 1x/day33(high risk areas excluded)6Imiquimod 1x/day33(high risk areas excluded)73.3Imiquimod 1x/day33(high risk areas excluded)87.9Imiquimod 1x/day33(high risk areas excluded)69.75-FU in PC10Limbs, trunk, head/neck905-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90*					
Imiquimod $7x$ /week179(high risk areas excluded)73Vehicle cream3602Vehicle cream360Imiquimod $7x$ /week84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream82Imiquimod $2x$ /day3Limbs, trunk, head/neck100Post-treatment excision12Imiquimod $1x$ /day33Iniquimod $1x$ /day35Iniquimod $1x$ /day35Iniquimod $1x$ /day90Post-treatment excision12Not investigatedI. on 15 -FU $1x$ /week, 6 weeksI. on 15 -FU $2x$ /week, 4 weeksI. on 5 m 15 -FU $2x$ /week, 4 weeksI. on 5 m 15 -FU $2x$ /week, 4 weeksI. on 5 m 15 -FU $2x$ /week, 4 weeksI. on 5 m 15 -FU	Imiquimod $7x$ /week179(high risk areas excluded)73Vehicle cream3603602Imiquimod $7x$ /week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Imiquimod $2x$ /day3Limbs, trunk, head/neck100Imiquimod $1x$ /day33(high risk areas excluded)6Imiquimod $1x$ /day33(high risk areas excluded)6Imiquimod $1x$ /day33(high risk areas excluded)73.3Imiquimod $1x$ /day, $3x$ /week30Inibs, trunk, head/neck905-FU in PC10Limbs, trunk, head/neck900.5 ml 5 -FU ix petrolatum7(facial BCC)571.0 ml 5 -FU $1x$ /week, 6 weeks20Limbs, trunk, head/neck90*		Post-treatment excision	12	Not investigated	Dosing 5x/week equally effective to 7x/week. Because of
Vehicle cream3602Imiquimod $7x$ / week84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream82(high risk areas excluded)6Not investigatedIniquimod $2x/day$ 12Not investigatedImiquimod $2x/day$ 3Limbs, trunk, head/neck100Post-treatment excision12Not investigatedImiquimod $2x/day$ 33(high risk areas excluded)87.987.9Not investigatedImiquimod $2x/day$, $3x/week33(high risk areas excluded)87.9Not investigatedImiquimod 2x/day, 3x/week33(high risk areas excluded)87.9Not investigatedImiquimod 1x/day, 3x/week33(high risk areas excluded)87.9Not investigatedImiquimod 1x/day, 3x/week33Limbs, trunk, head/neck90Post-treatment excision12Not investigated5-FU in PC10Dimestrum7(facial BCC)5790.9Post-treatment excision12Not investigated0.5 ml 5-FU 1x/week, 6 weeks10Dist-treatment excision12Not investigated0.50.5 ml 5-FU 1x/week, 4 weeks90.90.5 ml 5-FU 1x/week, 4 weeks10Dist-treatment excision12Not investigated0.5 ml 5-FU 2x/week, 4 weeks100.90.5 ml 5-FU 2x/week, 4 weeks17100.90.5 ml 5-FU 2x/week, 4 weeks17100.9$	Vehicle cream3602Imiquimod $7x$ / week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Vehicle cream3Limbs, trunk, head/neck80Imiquimod $2x/day$ 3(high risk areas excluded)6Imiquimod $1x/day$ 33(high risk areas excluded)73.3Imiquimod $1x/day$ 33(high risk areas excluded)73.3Imiquimod $1x/day$ 3.3(high risk areas excluded)87.9Imiquimod $1x/day$ 3.4/week3073.3S-FU in PC10Limbs, trunk, head/neck905-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90 ^a					improved safety profile with 5×/week dosing and similar
Imiquimod 7x/ week84Limbs, trunk, head/neck80Post-treatment excision12Not investigatedVehicle cream82(high risk areas excluded)699999Imiquimod $2x/day$ 3Limbs, trunk, head/neck100Post-treatment excision12Not investigatedImiquimod $2x/day$ 33(high risk areas excluded)87.99999Imiquimod $2x/day$, $3x/week33(high risk areas excluded)87.9999Imiquimod 2x/day, 3x/week33(high risk areas excluded)87.9999Imiquimod 2x/day, 3x/week33Limbs, trunk, head/neck90Post-treatment excision12Not investigated5-FU in PC10101095Post-treatment excision12Not investigated0.5 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90"90"90"0.5 ml 5-FU 1x/week, 4 weeks100%0.5 ml 5-FU 1x/week, 4 weeks100.5 ml 5-FU 2x/week, 4 weeks100"90"90"0.5 ml 5-FU 2x/week, 4 weeks100"0.5 ml 5-FU 2x/week, 4 weeks17100"10"10"10"10"$	Imiquimod 7x/ week84Limbs, trunk, head/neck80Vehicle cream82(high risk areas excluded)6Imiquimod 2x/day3Limbs, trunk, head/neck100Imiquimod 1x/day33(high risk areas excluded)87.9Imiquimod 1x/day33(high risk areas excluded)87.9Imiquimod 1x/day33(high risk areas excluded)87.9Imiquimod 1x/day3.4(high risk areas excluded)87.95-FU in PC10Limbs, trunk, head/neck905-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90 ^a					clearance rates, the 5x/week regimen is recommended
Vehicle cream82(high risk areas excluded)6Imiquimod $2x/day$ 3Limbs, trunk, head/neck100Post-treatment excision12Not investigatedImiquimod $2x/day$ 33(high risk areas excluded)87.973.3Not investigatedImiquimod $2x/day$, $3x/week$ 30(high risk areas excluded)87.973.3Imiquimod $2x/day$, $3x/week$ 33(high risk areas excluded)87.9905-FU in PC10Limbs, trunk, head/neck90Post-treatment biopsy16100% excellent5-FU in PC10Limbs, trunk, head/neck90"Post-treatment excision12Not investigated0.5 ml 5-FU 1x/week, 6 weeks21(high risk areas excluded)95"94"0.5 ml 5-FU 1x/week, 6 weeks190.5 ml 5-FU 1x/week, 6 weeks190.5 ml 5-FU 2x/week, 4 weeks100"0.5 ml 5-FU 1x/week, 4 weeks140.5 ml 5-FU 1x/week, 4 weeks100"91"0.5 ml 5-FU 2x/week, 4 weeks100"0.5 ml 5-FU 2x/week, 4 weeks17100"10"10"10"10"	Vehicle cream82(high risk areas excluded)6Imiquimod 2x/day3Limbs, trunk, head/neck100Imiquimod 1x/day33(high risk areas excluded)87.9Imiquimod 1x/day33(high risk areas excluded)87.9Imiquimod 1x/day33(high risk areas excluded)73.3Imiquimod 1x/day3x/week3369.75-FU in PC10Limbs, trunk, head/neck905-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1x/week, 6 weeks20Limbs, trunk, head/neck90 ^a 0.5 ml 5-FU 1x/week, 6 weeks21(high risk areas excluded)93 ^a		Post-treatment excision	12	Not investigated	Imiquimod 5% cream 7×/week is a safe and effective
Imiquimod $2x/day$ 3Limbs, trunk, head/neck100Post-treatment excision12Not investigatedImiquimod $1x/day$ 33(high risk areas excluded)87.973.3Not investigatedImiquimod $2x/day$, $3x/week$ 3073.369.773.3Imiquimod $2x/day$, $3x/week$ 33(high risk areas excluded)87.91005-FU in PC10Limbs, trunk, head/neck90Post-treatment biopsy16100% excellent5-FU in petrolatum7(facial BCC)57100% excellent100% excellent0.5 ml 5-FU in petrolatum7(facial BCC)57Not investigated0.5 ml 5-FU in petrolatum7(facial BCC)57Not investigated0.5 ml 5-FU in petrolatum7(facial BCC)570.70.50.5 ml 5-FU 1x/week, 6 weeks1990 ^a Post-treatment excision12Not investigated0.5 ml 5-FU 1x/week, 4 weeks1979 ^a 0.579 ^a 0.50.50.50.5 ml 5-FU 2x/week, 4 weeks21100 ^a 90 ^a 90 ^a 90 ^a 0.5 ml 5-FU 2x/week, 4 weeks17100 ^a 10 ^a 10 ^a	Imiquimod 2×/day3Limbs, trunk, head/neck100Imiquimod 1×/day33(high risk areas excluded)87.9Imiquimod 2×/day, 3×/week3073.3Imiquimod 1×/day, 3×/week3369.75-FU in PC10Limbs, trunk, head/neck905-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1×/week, 6 weeks20Limbs, trunk, head/neck90 ^a	(t)				treatment for sBCC
Imiquimod 1×/day 33 (high risk areas excluded) 87.9 Imiquimod 2×/day, 3×/week 30 73.3 73.3 Imiquimod 2×/day, 3×/week 30 73.3 69.7 S-FU in PC 10 Limbs, trunk, head/neck 90 Post-treatment biopsy 16 100% excellent 5-FU in PC 10 Limbs, trunk, head/neck 90 Post-treatment biopsy 16 100% excellent 6.5-FU in petrolatum 7 (facial BCC) 57 10 100% excellent 6.5-FU in petrolatum 7 (facial BCC) 57 10 100% excellent 1.0 ml 5-FU 1x/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a Post-treatment excision 12 Not investigated 0.5 ml 5-FU 1x/week, 4 weeks 19 9 ^a 0 ^a 0 ^a 0 ^a 0.5 ml 5-FU 2×/week, 4 weeks 17 10 ^a 7 ^a 0 ^a 0 ^a	Imiquimod 1×/day33(high risk areas excluded)87.9Imiquimod 2×/day, 3×/week3073.3Imiquimod 1×/day, 3×/week3369.75-FU in PC10Limbs, trunk, head/neck905-FU in petrolatum7(facial BCC)571.0 ml 5-FU 1×/week, 6 weeks20Limbs, trunk, head/neck90*0.5 ml 5-FU 1×/week, 6 weeks21(high risk areas excluded)95*	_	Post-treatment excision	12	Not investigated	Highest efficacy, but unacceptable side-effects with 2x/
Imiquimod 2x/day, 3x/week 30 73.3 Imiquimod 1x/day, 3x/week 30 69.7 5-FU in PC 10 Limbs, trunk, head/neck 90 Post-treatment biopsy 16 100% excellent 5-FU in PC 10 Limbs, trunk, head/neck 90 Post-treatment biopsy 16 100% excellent 5-FU in petrolatum 7 (facial BCC) 57 100% excellent 100% excellent 1.0 ml 5-FU 1x/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a Post-treatment excision 12 Not investigated 0.5 ml 5-FU 1x/week, 6 weeks 19 94 ^a 79 ^a 0.5 ml 5-FU 2x/week, 4 weeks 19 79 ^a 0.5 ml 5-FU 2x/week, 4 weeks 19 79 ^a 0.5 ml 5-FU 2x/week, 4 weeks 100 ^a	Imiquimod 2×/day, 3×/week 30 73.3 Imiquimod 1×/day, 3×/week 33 69.7 5-FU in PC 10 Limbs, trunk, head/neck 90 5-FU in petrolatum 7 (facial BCC) 57 1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a					day dosing
Imiquimod 1×/day, 3×/week 33 69.7 5-FU in PC 10 Limbs, trunk, head/neck 90 Post-treatment biopsy 16 100% excellent 5-FU in petrolatum 7 (facial BCC) 57 10 100% excellent 1.0 ml 5-FU lx/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a Post-treatment biopsy 16 100% excellent 0.5 ml 5-FU lx/week, 6 weeks 21 (high risk areas excluded) 95 ^a Post-treatment excision 12 Not investigated 0.5 ml 5-FU 1x/week, 6 weeks 19 94 ^a 79 ^a 0.5 ml 5-FU 2×/week, 4 weeks 19 0 ^a 0.5 ml 5-FU 2×/week, 4 weeks 19 79 ^a 0.5 ml 5-FU 3×/week, 4 weeks 100 ^a	Imiquimod 1×/day, 3×/week 33 69.7 5-FU in PC 10 Limbs, trunk, head/neck 90 5-FU in petrolatum 7 (facial BCC) 57 1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a	73.3				
5-FU in PC 10 Limbs, trunk, head/neck 90 Post-treatment biopsy 16 100% excellent 5-FU in petrolatum 7 (facial BCC) 57 100% excellent 1.0 ml 5-FU 1x/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a Post-treatment biopsy 16 100% excellent 0.5 ml 5-FU 1x/week, 6 weeks 21 (high risk areas excluded) 95 ^a 10 10 <td< td=""><td>5-FU in PC 10 Limbs, trunk, head/neck 90 5-FU in petrolatum 7 (facial BCC) 57 1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90^a 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95^a</td><td></td><td></td><td></td><td></td><td></td></td<>	5-FU in PC 10 Limbs, trunk, head/neck 90 5-FU in petrolatum 7 (facial BCC) 57 1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a					
5-FU in petrolatum 7 (facial BCC) 57 100% excellent 1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a Post-treatment excision 12 Not investigated 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a Post-treatment excision 12 Not investigated 0.5 ml 5-FU 1×/week, 6 weeks 19 94 ^a 94 ^a 79 ^a 0.5 ml 5-FU 1×/week, 4 weeks 19 79 ^a 0.5 ml 5-FU 1×/week, 4 weeks 19 79 ^a 79 ^a 0.5 ml 5-FU 3×/week, 4 weeks 17 100 ^a	5-FU in petrolatum 7 (facial BCC) 57 1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a		Post-treatment biopsy	16	100% excellent	Increase in short-term eradication of BCC using PC-based
1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a Post-treatment excision 12 Not investigated 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a 94 ^a 1.0 ml 5-FU 1×/week, 6 weeks 18 94 ^a 94 ^a 94 ^a 0.5 ml 5-FU 1×/week, 6 weeks 19 79 ^a 79 ^a 0.5 ml 5-FU 1×/week, 4 weeks 21 90 ^a 0.5 ml 5-FU 3×/week, 4 weeks 17 100 ^a	1.0 ml 5-FU 1×/week, 6 weeks 20 Limbs, trunk, head/neck 90 ^a 0.5 ml 5-FU 1×/week, 6 weeks 21 (high risk areas excluded) 95 ^a				100% excellent	vehicle, but not statistically significant
21 (high risk areas excluded) 95 ^a 18 94 ^a 19 79 ^a 21 90 ^a 17 100 ^a	21 (high risk areas excluded)		Post-treatment excision	12	Not investigated	Treatment with intralesional 5-FU epigel is both safe and
18 19 21 17 1						effective ^a
19 21 17	18	94ª				
4 weeks 21 4 weeks 17 1	19	79ª				
17	4 weeks 21	90ª				
	17	100^{a}				

		BCC,		Clearance	FU period		
Ref.	Intervention	n	Localization	rate (%)	(months)	Cosmetic outcome	Conclusion
Nodı	ılar basal cell ce	arcinoma					
12	Excision	36	Face (scalpel and neck excluded)	98.3ª	48	87% good ^a	SE higher CR than RT ^a
	RT	41		92.5ª		69% good ^a	SE better CO than RT ^a
30	CS	51	Head and neck area	80.4	60	38.5% good ^b	SE and CS comparable CR
	Excision	45		91.6		79.8% good ^b	SE better CO than CS
31	Excision	53	Limbs, trunk, head/neck (high risk	96°	60	54% excellent/good	SE higher CR than MAL-PD
	MAL-PDT	52	areas excluded)	86 °		87% excellent/good	
32	Excision		All (BCC on concave areas excluded)	97.7	36	Not investigated	SE higher CR than ALA-PDT
	ALA-PDT			69.7		-	
Aggr	essively growing	g basal cei	ll carcinoma				
12	Excision	36	Face (scalpel and neck excluded)	98.3ª	48	87% good ^a	SE higher CR than RT ^a
	RT	41		92.5ª		69% good ^a	SE better CO than RT ^a
28	Excision	199	Face	95.9	60	Not investigated	SE and MMS comparable CR
	MMS	198		97.5		-	*
Recu	rrent basal cell	carcinoma	1				
28	Excision	100	Face	97.6	60	Not investigated	MMS higher CR than SE
	MMS	102		87.9		8	e

Table II. Randomized controlled trials investigating treatment of clinically and histologically confirmed nodular, aggressively growing or recurrent basal cell carcinoma (BCC)

^aResults for total study group, including other histological subtypes with no separate analysis available for nodular, aggressively growing and recurrent basal cell carcinoma, respectively, ^baverage of cosmetic evaluation of 6 persons including professionals and laymen, ^cnon-responders after 3 months excluded from this analysis.

PDT: photodynamic therapy; SE: surgical excision; CR: clearance rate; FU: follow-up; CO: cosmetic outcome; CS: cryosurgery; RT: radiotherapy; ALA: aminolevulinic acid; MAL: methyl aminolevulinate; MMS: Mohs' micrographic surgery.

linate (MAL-PDT) had 90.7% clearance of responding lesions and surgical excision (SE) 100% in small sBCC, but the cosmetic result was better for MAL-PDT (11). When radiotherapy (RT) was compared with SE in facial BCC, 4-year clearance rates of 98.3% and better cosmetic results were found after SE compared with 92.5 % in the RT group (12). Nodular, ulcerated, superficial, pagetoid and sclerosing BCC were included in this study and no separate clearance rates were given for sBCC.

Two trials compared MAL-PDT with cryotherapy (CT) in sBCC (13–15). The first study found 5-year clearance rates of 78% and 80%, respectively, with significantly better cosmetic results after MAL-PDT (13) and in the second study clearance rates for MAL-PDT (62%) seemed to be lower than those after cryotherapy (93.3%) (14).

Three RCTs evaluated efficacy of PDT in sBCC by comparing it with placebo or using different methods (16–18). Differences in preparation of the treated area, the type of photosensitizer, light source and illumination scheme that were used are probably responsible for the divergent clearance rates of 74–97% that were found. The maximum follow-up period was 2 years. Recurrence rates after long-term follow-up are expected to be higher, as it is known from the literature, that the number of recurrences after 5 years follow-up can be twice as high as those after a follow-up period of 2 years (8, 19).

Six RCTs have been conducted investigating imiquimod cream in treatment of sBCC (20–25). Histological examination of the treated area after 6 or 12 weeks was the end-point of the studies that were designed either to compare different dosing regimes or to compare imiquimod with a vehicle. The RCTs that specifically investigated sBCC found clearance rates of 73–100% with a high frequency dosing regime of six times weekly or more; however, unacceptable side-effects, such as erythema, crusting and severe erosion, were seen (22–25). Therefore the highest efficacy results with acceptable safety profiles were found in a 5-times-a-week dosage, showing clearance rates up to 80.8% (22, 23, 25).

The efficacy of 5-FU in sBCC was investigated in two RCTs. A pilot study in only 10 patients compared two vehicles and showed cure rates of up to 90% in lesions treated with 5-FU in phosphatidylcholine (26). In the second study 5-FU was administered intra-lesionally and showed complete histological clearance in all 17 patients who were treated 3 times a week for 2 weeks (27).

Nodular basal cell carcinoma

In 5 RCTs SE was compared with a different treatment modality in nodular basal cell carcinoma (nBCC) (Table II). One RCT comparing SE with Mohs' micrographic surgery (MMS) in facial primaryBCC showed no statistically significant difference in efficacy after 5 years of follow-up (28).

One RCT comparing cryosurgery to SE found no significant difference in efficacy, although cosmetic result after SE was better (29, 30). In both studies comparing SE to PDT after tumour-debulking, treatment with PDT appeared to be less effective than SE after long-term follow-up (31, 32). In facial BCC a higher efficacy and better cosmetic result was found after SE compared with RT, but separate analysis per histological subtype was missing (12).

Aggressive basal cell carcinoma

This subgroup included BCCs with infiltrating or miconodular growth patterns and basosquamous carcinoma (5, 7, 8). Two RCTs included aggressively growing BCCs among other subtypes (Table II). The difference in efficacy between MMS and SE was not statistically significant (28). However, due to larger defects following frequent incomplete excisions in aggressive BCC, the authors concluded that MMS is the preferred treatment for facial aggressive BCC (33). When comparing SE to RT, SE was significantly more effective than RT (12).

Recurrent basal cell carcinoma

Recurrent BCC (rBCC) is known to be a high-risk tumour with a worse prognosis than primary BCC (8, 34–36). This may be due to the fact that scar tissue can cover residual tumour fields or because the appearance of basaloid tumour cells in recurrent tumours is frequently squamified, lacy and morpheaform, which may be easily missed in scar tissue (35).

The only RCT investigating treatment modalities in rBCC showed that after 5 years of follow-up MMS is the preferred treatment for facial rBCC because of statistically significant lower recurrence rates (28) (Table II).

DISCUSSION

There are still many problems unsolved concerning the treatment of BCC. Some topics have not been investigated in RCTs, some issues are difficult to quantify, such as aesthetic outcome of treatments. Therefore, in clinical practice treatments may be performed without RCT evidence.

More RCTs would be desirable to clarify efficacy, aesthetic outcome and patient preference. A possible future study in sBCC might compare the efficacy of different non-invasive methods (PDT, imiquimod and 5-FU cream). It would also be interesting to investigate non-invasive treatments in *facial* sBCC.

In nBCCs at low-risk anatomical sites comparison of the efficacy of cryosurgery and curettage to SE would be useful. As only one RCT studied radiotherapy and techniques have been refined, indications for radiotherapy should be investigated. Furthermore, it would be interesting to investigate whether it is defendable to re-treat recurrent or residual tumour with a non-invasive therapy following an earlier non-invasive treatment or if it should be excised. Besides tumour characteristics, patient characteristics are of importance when choosing a treatment for an individual. In a few cases where surgery is impossible or undesirable, it may be advantageous to treat a patient with a different, possibly less effective, treatment.

CONCLUSION

Based on the available RCTs, we conclude that SE is the gold standard for treatment of BCC. MMS is preferable for facial rBCC or BCC with an aggressive histological subtype according to one RCT. Radiotherapy is a non-invasive and effective alternative treatment for nodular and aggressive BCC. Selected low-risk sBCCs may be treated with non-invasive treatments, such as PDT or imiquimod.

ACKNOWLEDGEMENTS

Funding source: NK and AA are financed by a grant of ZonMw (08-82310-98-08626).

The authors declare no conflict of interest.

REFERENCES

- 1. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007 (1): CD003412.
- de Vries E, Louwman M, Bastiaens M, de Gruijl F, Coebergh JW. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 2004; 123: 634–638.
- Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 1999; 81: 555–559.
- de Vries E, van de Poll-Franse LV, Louwman WJ, de Gruijl FR, Coebergh JW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152: 481–488.
- Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19 Suppl 2: S127–147.
- 6. Wade TR, Ackerman AB. The many faces of basal-cell carcinoma. J Dermatol Surg Oncol 1978; 4: 23–28.
- 7. Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32: 393–398.
- Smeets NW, Kuijpers DI, Nelemans P, Ostertag JU, Verhaegh ME, Krekels GA, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face – results of a retrospective study and review of the literature. Br J Dermatol 2004; 151: 141–147.
- 9. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177–1183.
- Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110: 880–884.

458 K. Mosterd et al.

- 11. Szeimies R, Ibbotson S, Murrell D, Rubel D, Frambach Y, de Berker D, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302–1311.
- Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997; 76: 100–106.
- Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547–553.
- 14. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832–840.
- 15. Basset-Seguin N. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. Br J Dermatol 2005; 153: 29.
- 16. Soler AM, Angell-Petersen E, Warloe T, Tausjo J, Steen HB, Moan J, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000; 71: 724–729.
- 17. Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004; 140: 26–32.
- de Haas ER, Kruijt B, Sterenborg HJ, Martino Neumann HA, Robinson DJ. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006; 126: 2679–2686.
- 19. Rowe DE, Carroll RJ, Day CL, Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315–328.
- 20. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227–1236.
- Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002–1007.
- 22. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722–733.
- 23. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial

basal cell carcinoma: a double-blind, randomized, vehiclecontrolled study. J Am Acad Dermatol 2002; 47: 390–398.

- 24. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939–947.
- 25. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807–813.
- 26. Romagosa R, Saap L, Givens M, Salvarrey A, He JL, Hsia SL, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg 2000; 26: 338–340.
- Miller BH, Shavin JS, Cognetta A, Taylor RJ, Salasche S, Korey A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997; 36: 72–77.
- Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9: 1149–1156.
- 29. Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000; 26: 759–764.
- Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 2007; 33: 579–587.
- Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photo-dynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131–1136.
- 32. Mosterd K, Thissen MR, Nelemans P, Kelleners-Smeets NW, Janssen RL, Broekhof KG, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159: 864–870.
- 33. Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364: 1766–1772.
- Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 1: overview. J Dermatol Surg Oncol 1991; 17: 713–718.
- 35. Rowe DE, Carroll RJ, Day CL, Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424–431.
- Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 1999; 141: 415–423.